Arima M, Yukawa T, Makino S
Department of Allergy and Clinical Immunology, Dokkyo University School of Medicine, Tochigi, Japan.
Chest. 1995 Aug;108(2):529-34. doi: 10.1378/chest.108.2.529.
We investigated the effects of YM264, a specific platelet-activating factor (PAF) antagonist, on the airway hyperresponsiveness (AH) and the late asthmatic response (LAR) of guinea pigs that were sensitized by exposure to aerosolized ovalbumin (OA). Respiratory resistance (Rrs) was determined by the oscillation technique. Airway responsiveness was evaluated by administering a dose of histamine at which the Rrs reached 200% of the baseline value (H200). Animals were administered 1 or 3 mg/kg of YM264 orally 30 min before and again at 3 h after exposure to OA. YM264 significantly suppressed AH 24 h after and 5 days after the exposure. YM264 also suppressed the development of the LAR and accumulation of eosinophils and neutrophils in the tracheal mucosa of guinea pigs. These observations suggest that PAF is involved in the AH and the development of the LAR in asthma. PAF antagonists may play a beneficial role in the treatment of asthma.
我们研究了特异性血小板活化因子（PAF）拮抗剂YM264对经雾化卵清蛋白（OA）致敏的豚鼠气道高反应性（AH）和迟发性哮喘反应（LAR）的影响。采用振荡技术测定呼吸阻力（Rrs）。通过给予组胺使Rrs达到基线值的200%（H200）来评估气道反应性。在暴露于OA前30分钟及暴露后3小时，给动物口服1或3mg/kg的YM264。YM264在暴露后24小时和5天显著抑制了AH。YM264还抑制了LAR的发展以及豚鼠气管黏膜中嗜酸性粒细胞和中性粒细胞的积聚。这些观察结果表明，PAF参与了哮喘中的AH和LAR的发展。PAF拮抗剂可能在哮喘治疗中发挥有益作用。
